Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms

Blood

Volumn 121, Issue 13, 2013, Pages 2522-2528

  Varettoni, Marzia ^a   Arcaini, Luca ^a   Zibellini, Silvia ^a   Boveri, Emanuela ^a   Rattotti, Sara ^a   Riboni, Roberta ^a   Corso, Alessandro ^a   Orlandi, Ester ^a   Bonfichi, Maurizio ^a   Gotti, Manuel ^a   Pascutto, Cristiana ^a   Mangiacavalli, Silvia ^a   Croci, Giorgio ^a   Fiaccadori, Valeria ^a   Morello, Lucia ^a   Guerrera, Maria Luisa ^a   Paulli, Marco ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN M; MYELOID DIFFERENTIATION FACTOR 88; LEUCINE; MYD88 PROTEIN, HUMAN; PROLINE;

ADULT; AGED; ALLELE; ARTICLE; B CELL CHRONIC LYMPHOPROLIFERATIVE DISORDER; BLOOD SAMPLING; BONE MARROW; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LYMPHATIC SYSTEM TUMOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; WALDENSTROEM MACROGLOBULINEMIA; WILD TYPE; AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; GENETICS; LYMPHOMA; MIDDLE AGED; MISSENSE MUTATION; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; LEUCINE; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MUTATION, MISSENSE; MYELOID DIFFERENTIATION FACTOR 88; PREVALENCE; PROLINE; WALDENSTROM MACROGLOBULINEMIA;

MLCS; MLOWN;

EID: 84878423649     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457101     Document Type: Article

References (33)

1. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;(30):110-115.
3. Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22): 4464-4471.
4. Kristinsson SY, Björkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008; 112(8):3052-3056.
5. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol. 2006;17(3): 488-494.
6. Campbell PJ, Stephens PJ, Pleasance ED, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 2008;40(6):722-729.
7. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature. 2011; 475(7354):101-105.
8. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26): 6904-6908.
9. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
10. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
11. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192-195.
12. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1): 188-191.
13. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9): 826-833.
14. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
15. Pham-Ledard A, Cappellen D, Martinez F, et al. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2012;132(8): 2118-2120.
16. Montesinos-Rongen M, Godlewska E, Brunn A, et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011; 122(6):791-792.
17. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
18. Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010; 115(17):3541-3552.
19. Isaacson PGPM, Berger F, Swerdlow SH, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; 2008:218-219
20. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
21. Ugo V, Leporrier N, Salaun V, et al. Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma. 2006;47(10): 2088-2095.
22. Goldaniga M, Ferrario A, Cortelazzo S, et al. A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol. 2008;83(5):349-354.
23. Arcaini L, Zibellini S, Passamonti F, et al. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Mol Dis. 2009;42(3):286-291.
24. Yan Q, Huang Y, Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97(4):595-598.
25. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930-4934.
26. Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):503-510.
27. Ocio EM, Hernandez JM, Mateo G, et al. Immunophenotypic and cytogenetic comparison of Waldenstrom’s macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005; 5(4):241-245.
28. Arcaini L, Varettoni M, Boveri E, et al. Distinctive clinical and histological features of Waldenstrom’s macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011; 11(1):103-105.
29. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367(23):2255-2256, author reply 2256-2257.
30. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119(19):4462-4466.
31. Morra E, Cesana C, Klersy C, et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia. 2004;18(9): 1512-1517.
32. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005; 23(21):4662-4668.
33. Kyle RA, Dispenzieri A, Kumar S, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom’s macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk. 2011;11(1):74-76.